Schizophrenia is a highly heterogeneous disorder with variable onset, symptom patterns, and long-term outcomes. The onset of schizophrenia is thought to arise from the interaction between neurobiological vulnerability and environmental exposures during development. The disease course is often fluctuating, with episodic exacerbations and periods of remission. Core symptom domains in schizophrenia include positive, negative, disorganization, cognitive, and affective. Each symptom domain of schizophrenia can follow distinct trajectories and may carry prognostic significance across stages of illness.

This slide deck was developed by Professor Dr.  Ana Catalán Alcántara, University of the Basque Country, Leioa, Spain; and Professor Dr. Christoph Correll, Charité – Universitätsmedizin Berlin, Germany, in collaboration with Cambridge (a division of Prime, Cambridge, UK).

Index for
slide deck

Course, natural history, and prognosis

Course, natural history, and prognosis
Course, natural history, and prognosis
file_download Download slide in HQ

Overview of the course and prognosis of schizophrenia

The course and prognosis of schizophrenia
The course and prognosis of schizophrenia
file_download Download slide in HQ

Symptom domains and early development in schizophrenia

Symptom domains and early development in schizophrenia
Symptom domains and early development in schizophrenia
file_download Download slide in HQ
Symptom domains in schizophrenia
Symptom domains in schizophrenia

The Liddle framework identifies psychomotor poverty (e.g., reduced speech and movement), disorganization (e.g., thought disorder and inappropriate affect), and reality distortion (e.g., delusions and hallucinations) as distinct but related syndromes.2 This model expanded …

file_download Download slide in HQ

Early course of schizophrenia

Early course of schizophrenia
Early course of schizophrenia
file_download Download slide in HQ
Transdiagnostic clinical staging
Transdiagnostic clinical staging

Traditional clinical staging is unidirectional and fails to account for the dynamic course of schizophrenia.1 Dynamic models may enhance prognosis prediction and guide individualized treatment, within and across stages.1

References:
1. Scott J, Iorfino F, Capon W, et al. …

file_download Download slide in HQ
Clinical high-risk for psychosis
Clinical high-risk for psychosis

Several assessment tools have been developed to identify individuals at clinical high risk for psychosis, particularly in the early stages before a full psychotic disorder emerges. Three key assessment tools are described below.

  • The CAARMS is a semi-structured interview …
file_download Download slide in HQ
Initial presentation in first-episode psychosis
Initial presentation in first-episode psychosis

In the figure, each circle (node) represents a symptom, and the lines between nodes represent statistical associations between symptoms.2 Symptoms are grouped by clinical scale: orange nodes represent depressive symptoms from the CDSS, blue nodes represent negative sympto…

file_download Download slide in HQ

Related content

Can we help children at familial high-risk of schizophrenia? play_circle Video play_circle
Can we help children at familial high-risk of schizophrenia?

Professor Dr. Merete Nordentoft introduces her work with the population of children of parents with schizophrenia. She also highlights the model implemented in Denmark, called VIA family, and why it is important to focus on children of parents living with schizophrenia.

28.04.2026 Schizophrenia
What are the recent innovations in the pharmacological treatment of schizophrenia? play_circle Video play_circle
What are the recent innovations in the pharmacological treatment of schizophrenia?

Professor Dr. Christoph Correll highlights the recent innovations in the pharmacological treatment of schizophrenia.

17.04.2026 Schizophrenia
Why is there a mortality gap in schizophrenia? play_circle Video play_circle
Why is there a mortality gap in schizophrenia?

Dr. Marco Solmi introduces what the mortality gap is and why there is a mortality gap in schizophrenia.

24.03.2026 Schizophrenia